Adıyaman Süleyman Cem, Alacacıoğlu İnci, Ersen Danyeli Ayça, Türkyılmaz Doğuş, Sevindik Ömür Gökmen, Demirkan Fatih, Pişkin Özden, Özcan Mehmet Ali, Ündar Bülent, Özkal Sermin, Özsan Güner Hayri
Dokuz Eylül University Faculty of Medicine, Department of Internal Medicine, İzmir, Turkey
Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey
Turk J Haematol. 2019 May 3;36(2):81-87. doi: 10.4274/tjh.galenos.2019.2018.0219. Epub 2019 Feb 6.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). The treatment of older NHL patients has always been a struggle; however, treatment statistics have begun showing favorable results similar to those of younger DLBCL patients thanks to newer treatment protocols. Here, we analyze the progress of our own elderly DLBCL patients who were followed between 2000 and 2016 in our center.
Eighty-seven DLBCL patients, who were diagnosed and treated in the Dokuz Eylül University Department of Hematology between 2000 and 2016, were included in this study. Median age was 72 (65-89) years and 13 (14.9%) patients were older than 80 years.
Median follow-up time was 19 months and 45 patients (51.7%) died during the follow-up period. Median overall survival (OS) was 55 months and median progression-free survival was calculated as 27 months. Sixty-three patients (72.4%) received standard R-CHOP therapy. Complete response was seen in 46 (52.9%) patients. The median survival time for patients who had complete response was 136 months (p<0.001); however, OS was not statistically different between older (>80 years) and younger patients (p=0.236).
According to our findings, we think that being able to complete standard R-CHOP therapy is vital for the survival rate of elderly DLBCL patients.
弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤（NHL）类型。老年NHL患者的治疗一直颇具挑战；然而，由于采用了更新的治疗方案，治疗统计数据已开始显示出与年轻DLBCL患者相似的良好结果。在此，我们分析了2000年至2016年间在我们中心接受随访的老年DLBCL患者的治疗进展。
本研究纳入了2000年至2016年间在多库兹艾吕尔大学血液科诊断并接受治疗的87例DLBCL患者。中位年龄为72（65 - 89）岁，13例（14.9%）患者年龄超过80岁。
中位随访时间为19个月，45例患者（51.7%）在随访期间死亡。中位总生存期（OS）为55个月，中位无进展生存期计算为27个月。63例患者（72.4%）接受了标准的R-CHOP治疗。46例（52.9%）患者出现完全缓解。完全缓解患者的中位生存时间为136个月（p<0.001）；然而，年龄较大（>80岁）和较年轻患者之间的总生存期无统计学差异（p = 0.236）。
根据我们的研究结果，我们认为能够完成标准的R-CHOP治疗对老年DLBCL患者的生存率至关重要。
